» Articles » PMID: 16155105

Desferoxamine and Ethyl-3,4-dihydroxybenzoate Protect Myocardium by Activating NOS and Generating Mitochondrial ROS

Overview
Date 2005 Sep 13
PMID 16155105
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

Protection from a prolyl hydroxylase domain-containing enzyme (PHD) inhibitor, desferoxamine (DFO), was recently reported to be dependent on production of reactive oxygen species (ROS). Ischemic preconditioning triggers the protected state by stimulating nitric oxide (NO) production to open mitochondrial ATP-sensitive K+ (mitoK(ATP)) channels, generating ROS required for protection. We tested whether DFO and a second PHD inhibitor, ethyl-3,4-dihydroxybenzoate (EDHB), might have similar mechanisms. EDHB and DFO increased ROS generation by 50-75% (P < 0.001) in isolated rabbit cardiomyocytes. This increase after EDHB exposure was blocked by N(omega)-nitro-L-arginine methyl ester (L-NAME), an NO synthase (NOS) inhibitor; ODQ, a guanylyl cyclase antagonist; and Rp-8-bromoguanosine-3',5'-cyclic monophosphorothioate Rp isomer, a PKG blocker, thus implicating the NO pathway in EDHB's signaling. Glibenclamide, a nonselective K(ATP) channel blocker, or 5-hydroxydecanoate, a selective mitoK(ATP) channel antagonist, also prevented EDHB's ROS production, as did blockade of mitochondrial electron transport with myxothiazol. NOS is activated by Akt. However, neither wortmannin, an inhibitor of phosphatidylinositol-3-kinase, nor Akt inhibitor blocked EDHB-induced ROS generation, indicating that EDHB initiates signaling downstream of Akt. DFO also increased ROS production, and this effect was blocked by ODQ, 5-hydroxydecanoate, and N-(2-mercaptopropionyl)glycine, an ROS scavenger. DFO increased cardiomyocyte production of nitrite, a metabolite of NO, and this effect was blocked by an inhibitor of NOS. DFO also spared ischemic myocardium in intact hearts. This infarct-sparing effect was blocked by ODQ, L-NAME, and N-(2-mercaptopropionyl)glycine. Hence, DFO and EDHB stimulate NO-dependent activation of PKG to open mitoK(ATP) channels and produce ROS, which act as second messengers to trigger entrance into the preconditioned state.

Citing Articles

An emerging double‑edged sword role of ferroptosis in cardiovascular disease (Review).

Qin S, Zhu C, Chen C, Sheng Z, Cao Y Int J Mol Med. 2024; 55(1).

PMID: 39540363 PMC: 11573318. DOI: 10.3892/ijmm.2024.5457.


Metabolomic signatures of carfilzomib-related cardiotoxicity in patients with multiple myeloma.

Shabnaz S, Nguyen T, Williams R, Rubinstein S, Garrett T, Tantawy M Clin Transl Sci. 2024; 17(5):e13828.

PMID: 38783568 PMC: 11116757. DOI: 10.1111/cts.13828.


Therapeutic Approaches Targeting Ferroptosis in Cardiomyopathy.

Ruan Y, Zhang L, Zhang L, Zhu K Cardiovasc Drugs Ther. 2023; .

PMID: 37930587 DOI: 10.1007/s10557-023-07514-4.


Iron accumulation and lipid peroxidation: implication of ferroptosis in diabetic cardiomyopathy.

Yan X, Xie Y, Liu H, Huang M, Yang Z, An D Diabetol Metab Syndr. 2023; 15(1):161.

PMID: 37468902 PMC: 10355091. DOI: 10.1186/s13098-023-01135-5.


Ethyl Protocatechuate Encapsulation in Solid Lipid Nanoparticles: Assessment of Pharmacotechnical Parameters and Preliminary In Vitro Evaluation for Colorectal Cancer Treatment.

Russo S, Torrisi C, Cardullo N, Muccilli V, La Mantia A, Castelli F Pharmaceutics. 2023; 15(2).

PMID: 36839716 PMC: 9958676. DOI: 10.3390/pharmaceutics15020394.